Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Khine S. Shan,Amalia Bonano-Rios,Nyein Wint Yee Theik,Atif Hussein,Marcelo Blaya

DOI: https://doi.org/10.3390/ijms25041973

IF: 5.6

2024-02-07

International Journal of Molecular Sciences

Abstract:The dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream substrates has been shown to be effective in preclinical studies and phase III trials with the approval of several PI3K pathway inhibitors by the Food and Drug Administration (FDA) over the past decade. However, the limited clinical efficacy of these inhibitors, intolerable toxicities, and acquired resistances limit the clinical application of PI3K inhibitors. This review discusses the PI3K signaling pathway, alterations in the PI3K pathway causing carcinogenesis, current and novel PI3K pathway inhibitors, adverse effects, resistance mechanisms, challenging issues, and future directions of PI3K pathway inhibitors.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

This paper aims to explore the molecular targeted therapy of phosphatidylinositol - 3 - kinase (PI3K) signaling pathway in various cancers. Specifically, the paper focuses on the following points:

1. **Overview of the PI3K Signaling Pathway**: The paper first introduces the basic mechanisms of the PI3K/AKT/mTOR signaling pathway, including its important roles in cell transcription, translation, proliferation, growth, survival, metabolism, and angiogenesis.

2. **The Role of the PI3K Pathway in Cancer**: The paper discusses in detail the abnormal activation of the PI3K pathway in different types of cancers and the mechanisms leading to carcinogenesis. For example, mutations and amplifications of the PI3K pathway are common in many cancers, such as breast cancer, lung cancer, and prostate cancer.

3. **Research Progress of PI3K Inhibitors**: The paper reviews the currently FDA - approved PI3K inhibitors and the new inhibitors under research. These inhibitors include pan - PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors.

4. **Clinical Application Challenges of PI3K Inhibitors**: The paper points out that although PI3K inhibitors have shown certain efficacy in pre - clinical studies and some phase III trials, their clinical application still faces many challenges, including limited clinical efficacy, intolerable toxicity, and acquired drug resistance.

5. **Future Directions**: Finally, the paper discusses the future research directions of PI3K inhibitors, including strategies to overcome drug resistance, combination treatment regimens, and the application of personalized medicine.

In conclusion, this paper attempts to comprehensively summarize the role of the PI3K signaling pathway in cancer and the latest progress in its targeted therapy, and also explores the current problems and future solutions.